All Stories

  1. International Union of Basic and Clinical Pharmacology. CVII. Structure and Pharmacology of the Apelin Receptor with a Recommendation that Elabela/Toddler Is a Second Endogenous Peptide Ligand
  2. International Union of Basic and Clinical Pharmacology CIII: Chemerin Receptors CMKLR1 (Chemerin1) and GPR1 (Chemerin2) Nomenclature, Pharmacology, and Function
  3. THE CONCISE GUIDE TO PHARMACOLOGY 2017/18: G protein-coupled receptors
  4. THE CONCISE GUIDE TO PHARMACOLOGY 2017/18: Overview
  5. Pharmacological targeting of apelin impairs glioblastoma growth
  6. Detection of Atherosclerotic Inflammation by 68 Ga-DOTATATE PET Compared to [ 18 F]FDG PET Imaging
  7. Vascular Imaging With 18 F-Fluorodeoxyglucose Positron Emission Tomography Is Influenced by Hypoxia
  8. 18 F-Fluoride and 18 F-Fluorodeoxyglucose Positron Emission Tomography After Transient Ischemic Attack or Minor Ischemic StrokeCLINICAL PERSPECTIVE
  9. [Pyr1]Apelin-13(1–12) Is a Biologically Active ACE2 Metabolite of the Endogenous Cardiovascular Peptide [Pyr1]Apelin-13
  10. Elabela/Toddler Is an Endogenous Agonist of the Apelin APJ Receptor in the Adult Cardiovascular System, and Exogenous Administration of the Peptide Compensates for the Downregulation of Its Expression in Pulmonary Arterial HypertensionClinical Perspective
  11. OUP accepted manuscript
  12. Smooth Muscle Endothelin B Receptors Regulate Blood Pressure but Not Vascular Function or Neointimal RemodelingNovelty and Significance
  13. Chemerin Elicits Potent Constrictor Actions via Chemokine‐Like Receptor 1 (CMKLR1), not G‐Protein‐Coupled Receptor 1 (GPR1), in Human and Rat Vasculature
  14. Cardiac action of the first G protein biased small molecule apelin agonist
  15. Endothelin ETA receptors predominate in chronic thromboembolic pulmonary hypertension
  16. The endothelin hormones, structure and function
  17. The Prodomain-bound Form of Bone Morphogenetic Protein 10 Is Biologically Active on Endothelial Cells
  18. The Concise Guide to PHARMACOLOGY 2015/16: G protein-coupled receptors
  19. The Concise Guide to PHARMACOLOGY 2015/16: Overview
  20. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands
  21. Apelin, Elabela/Toddler, and biased agonists as novel therapeutic agents in the cardiovascular system
  22. Identifying active vascular microcalcification by 18F-sodium fluoride positron emission tomography
  23. LGR5 Activates Noncanonical Wnt Signaling and Inhibits Aldosterone Production in the Human Adrenal
  24. Endothelin Receptors and Their Antagonists
  25. Design, Characterization, and First-In-Human Study of the Vascular Actions of a Novel Biased Apelin Receptor Agonist
  26. Endothelin@25 - new agonists, antagonists, inhibitors and emerging research frontiers: IUPHAR Review 12
  27. Changes in biomechanical properties of the coronary artery wall contribute to maintained contractile responses to endothelin-1 in atherosclerosis
  28. Modulation of endothelin receptors in the failing right ventricle of the heart and vasculature of the lung in human pulmonary arterial hypertension
  29. In Vivo Mapping of Vascular Inflammation Using the Translocator Protein Tracer 18 F-FEDAA1106
  30. Characterization of [125I]GLP-1(9-36), a novel radiolabeled analog of the major metabolite of glucagon-like peptide 1 to a receptor distinct from GLP1-R and function of the peptide in murine aorta
  31. The CCR5 chemokine receptor mediates vasoconstriction and stimulates intimal hyperplasia in human vessels in vitro
  32. The Concise Guide to PHARMACOLOGY 2013/14: Overview
  33. The IUPHAR/BPS Guide to PHARMACOLOGY: an expert-driven knowledgebase of drug targets and their ligands
  34. Evolving pharmacology of orphan GPCRs: IUPHAR Commentary
  35. No evidence for a local renin-angiotensin system in liver mitochondria
  36. Somatic mutations in ATP1A1 and CACNA1D underlie a common subtype of adrenal hypertension
  37. Screening β-Arrestin Recruitment for the Identification of Natural Ligands for Orphan G-Protein–Coupled Receptors
  38. International Union of Basic and Clinical Pharmacology. LXXXVIII. G Protein-Coupled Receptor List: Recommendations for New Pairings with Cognate Ligands
  39. Endothelin-2, the forgotten isoform: emerging role in the cardiovascular system, ovarian development, immunology and cancer
  40. Themed section: endothelin
  41. IUPHAR-DB: updated database content and new features
  42. The dual endothelin converting enzyme/neutral endopeptidase inhibitor SLV-306 (daglutril), inhibits systemic conversion of big endothelin-1 in humans
  43. Comparison of endothelin receptors in normal versus cirrhotic human liver and in the liver from endothelial cell-specific ETB knockout mice
  44. Comparison of human ETA and ETB receptor signalling via G-protein and β-arrestin pathways
  45. Defining the affinity and receptor sub-type selectivity of four classes of endothelin antagonists in clinically relevant human cardiovascular tissues
  46. The Twelfth International Conference on Endothelin (ET-12), Cambridge 2011
  47. GuideToPharmacology.org - an update
  48. Cellular Localization of Receptors Using Antibodies Visualized by Light and Dual Labeling Confocal Microscopy
  49. Dynamic In Vivo Imaging of Receptors in Small Animals Using Positron Emission Tomography
  50. How to Use the IUPHAR Receptor Database to Navigate Pharmacological Data
  51. Quantitative Phosphor Imaging Autoradiography of Radioligands for Positron Emission Tomography
  52. Radioligand Binding Assays and Their Analysis
  53. Receptor Binding Techniques
  54. Inotropic Action of the Puberty Hormone Kisspeptin in Rat, Mouse and Human: Cardiovascular Distribution and Characteristics of the Kisspeptin Receptor
  55. Importance of Subtype Selectivity for Endothelin Receptor Antagonists in the Human Vasculature
  56. Discovery of a Competitive Apelin Receptor (APJ) Antagonist
  57. Chemokine receptor CCR5: from AIDS to atherosclerosis
  58. Pharmacology of Renal Endothelin Receptors
  59. International Union of Basic and Clinical Pharmacology. LXXVII. Kisspeptin Receptor Nomenclature, Distribution, and Function
  60. Evidence for a novel vasospastic transmitter system, neuromedin U, in the equine digital circulation
  61. International Union of Basic and Clinical Pharmacology. LXXIV. Apelin Receptor Nomenclature, Distribution, Pharmacology, and Function
  62. Endothelial cell-specific ETBreceptor knockout: autoradiographic and histological characterisation and crucial role in the clearance of endothelin-1This article is one of a selection of papers published in the two-part special issue entitled 20 Years o...
  63. Evaluation of translocator protein quantification as a tool for characterising macrophage burden in human carotid atherosclerosis
  64. Introduction
  65. Modulation of the apelin/APJ system in heart failure and atherosclerosis in man
  66. Positron emission tomography of [18F]-big endothelin-1 reveals renal excretion but tissue-specific conversion to [18F]-endothelin-1 in lung and liver
  67. EDITORIAL
  68. The endothelin system in pulmonary and renal vasculopathy: les liaisons dangereuses
  69. FDG–PET can distinguish inflamed from non-inflamed plaque in an animal model of atherosclerosis
  70. Emerging pharmacology and physiology of neuromedin U and the structurally related peptide neuromedin S
  71. [Pyr1]Apelin-13 Identified as the Predominant Apelin Isoform in the Human Heart: Vasoactive Mechanisms and Inotropic Action in Disease
  72. International Union of Pharmacology. LXXII. Recommendations for Trace Amine Receptor Nomenclature
  73. Regional heterogeneity in the haemodynamic responses to urotensin II infusion in relation to UT receptor localisation
  74. Kisspeptins: a multifunctional peptide system with a role in reproduction, cancer and the cardiovascular system
  75. Positron emission tomography using 18F-labelled endothelin-1 reveals prevention of binding to cardiac receptors owing to tissue-specific clearance by ETB receptors in vivo
  76. Expression and vasoconstrictor function of anorexigenic peptides neuromedin U-25 and S in the human cardiovascular system
  77. IUPHAR-DB: the IUPHAR database of G protein-coupled receptors and ion channels
  78. Automated synthesis of the generic peptide labelling agent N-succinimidyl 4-[18F]fluorobenzoate and application to 18F-label the vasoactive transmitter urotensin-II as a ligand for positron emission tomography
  79. Chronic Apoptosis of Vascular Smooth Muscle Cells Accelerates Atherosclerosis and Promotes Calcification and Medial Degeneration
  80. Immunocytochemical localization of the urotensin-II receptor, UT, to rat and human tissues: Relevance to function
  81. Haemodynamic and renal effects of endothelin receptor antagonism in patients with chronic kidney disease
  82. Strategy for improved [11C]DAA1106 radiosynthesis and in vivo peripheral benzodiazepine receptor imaging using microPET, evaluation of [11C]DAA1106
  83. Kisspeptins Are Novel Potent Vasoconstrictors in Humans, with a Discrete Localization of Their Receptor, G Protein-Coupled Receptor 54, to Atherosclerosis-Prone Vessels
  84. Endothelin Receptors
  85. Urotensin-II Receptor
  86. ET-B Endothelin Receptor
  87. ET-A Endothelin Receptor
  88. Characterization of the snake venom ligand [125I]-DNP binding to natriuretic peptide receptor-A in human artery and potent DNP mediated vasodilatation
  89. Apoptosis of vascular smooth muscle cells induces features of plaque vulnerability in atherosclerosis
  90. Neuropeptide B and W: neurotransmitters in an emerging G-protein-coupled receptor system
  91. Novel Snake Venom Ligand Dendroaspis Natriuretic Peptide Is Selective for Natriuretic Peptide Receptor-A in Human Heart: Downregulation of Natriuretic Peptide Receptor-A in Heart Failure
  92. Deletion of Endothelial Cell Endothelin B Receptors Does Not Affect Blood Pressure or Sensitivity to Salt
  93. Functional and immunocytochemical evidence for a role of ghrelin and des-octanoyl ghrelin in the regulation of vascular tone in man
  94. International Union of Pharmacology. LVI. Ghrelin Receptor Nomenclature, Distribution, and Function
  95. Triptan-induced contractile (5-HT1Breceptor) responses in human cerebral and coronary arteries: relationship to clinical effect
  96. Emerging roles of apelin in biology and medicine
  97. Regulation of vascular reactivity by established and emerging GPCRs
  98. International Union of Pharmacology. XLVI. G Protein-Coupled Receptor List
  99. Receptor Binding Techniques
  100. Immunocytochemical localisation of the apelin receptor, APJ, to human cardiomyocytes, vascular smooth muscle and endothelial cells
  101. Alternative Pathway to Endothelin-Converting Enzyme for the Synthesis of Endothelin in Human Blood Vessels
  102. Comparison of Endothelin-A and Endothelin-B Receptor Distribution Visualized by Radioligand Binding versus Immunocytochemical Localization using Subtype Selective Antisera
  103. Down-regulation of ETA Receptors in ETB Receptor-deficient Mice
  104. Endothelin Receptor Pharmacology and Function in the Mouse: Comparison with Rat and Man
  105. In Vivo Imaging of Cardiovascular Endothelin Receptors Using the Novel Radiolabelled Antagonist [18F]-SB209670 and Positron Emission Tomography (microPET)
  106. CRF2receptors are highly expressed in the human cardiovascular system and their cognate ligands urocortins 2 and 3 are potent vasodilators
  107. Cellular distribution of immunoreactive urotensin-II in human tissues with evidence of increased expression in atherosclerosis and a greater constrictor response of small compared to large coronary arteries
  108. Regional Hemodynamic Actions of Selective Corticotropin-Releasing Factor Type 2 Receptor Ligands in Conscious Rats
  109. Identification and cellular localisation of NPW1 (GPR7) receptors for the novel neuropeptide W-23 by [125I]-NPW radioligand binding and immunocytochemistry
  110. Immunocytochemical localization of the endogenous vasoactive peptide apelin to human vascular and endocardial endothelial cells
  111. Maternal Dexamethasone Increases Endothelin-1 Sensitivity and Endothelin A Receptor Expression in Ovine Foetal Placental Arteries
  112. Peptide and trace amine orphan receptors: prospects for new therapeutic targets
  113. Translating the human genome: renaissance of cardiovascular receptor pharmacology
  114. Emerging roles for orphan G-protein-coupled receptors in the cardiovascular system
  115. Life before birth: effects of cortisol on future cardiovascular and metabolic function*
  116. Is urotensin-II the new endothelin?
  117. Comparison of vasodilators in human internal mammary artery: ghrelin is a potent physiological antagonist of endothelin-1
  118. Peptide Research Protocols
  119. International Union of Pharmacology. XXIX. Update on Endothelin Receptor Nomenclature
  120. Imaging Atherosclerotic Plaque Inflammation With [18F]-Fluorodeoxyglucose Positron Emission Tomography
  121. Discovery of recently adopted orphan receptors for apelin, urotensin II, and ghrelin identified using novel radioligands and functional role in the human cardiovascular system
  122. Of mice and men: advances in endothelin research and first antagonist gains FDA approval
  123. Comparison of the vasoconstrictor effects of rizatriptan and sumatriptan in human isolated cranial arteries: immunohistological demonstration of the involvement of 5-HT1B-receptors
  124. Radioligand binding reveals chymase as the predominant enzyme for mediating tissue conversion of angiotensin I in the normal human heart
  125. Thromboxane receptor density is increased in human cardiovascular disease with evidence for inhibition at therapeutic concentrations by the AT1receptor antagonist losartan
  126. Vasoconstrictor activity of novel endothelin peptide, ET-1(1 - 31), in human mammary and coronary arteriesin vitro
  127. [125I-His9]-Ghrelin, a novel radioligand for localizing GHS orphan receptors in human and rat tissue; up-regulation of receptors with atherosclerosis
  128. Physiological antagonism of endothelin-1 in human conductance and resistance coronary artery
  129. Depressor and regionally-selective vasodilator effects of human and rat urotensin II in conscious rats
  130. The endothelin system in human saphenous vein graft disease
  131. [125I]-(Pyr1)Apelin-13 is a novel radioligand for localizing the APJ orphan receptor in human and rat tissues with evidence for a vasoconstrictor role in man
  132. Nitric oxide-mediated modulation of the endothelin-1 signalling pathway in the human cardiovascular system
  133. Orphan-receptor ligand human urotensin II: receptor localization in human tissues and comparison of vasoconstrictor responses with endothelin-1
  134. Endothelin receptor antagonism in patients with chronic heart failure
  135. Urotensin II: fish neuropeptide catches orphan receptor
  136. Preface
  137. Cellular Expression of Isoforms of Endothelin-Converting Enzyme-1 (ECE-1c, ECE-1b and ECE-1a) and Endothelin-Converting Enzyme-2
  138. Changes in ETA-, AT1- and AT2-Receptors in the Phenotypically Transformed Intimal Smooth Muscle Layer of Human Atherosclerotic Coronary Arteries
  139. Endothelin-A-Receptors in Human Aorta and Pulmonary Arteries are Downregulated in Patients With Cardiovascular Disease
  140. Expression and Characterization of the Human Endothelin-A-Receptor in Pichia pastoris
  141. No Alteration in Vasoconstrictor Endothelin-B-Receptor Density or Function in Human Coronary Artery Disease
  142. Novel Nitric Oxide Donors Reverse Endothelin-1-Mediated Constriction in Human Blood Vessels
  143. Syntheses of the First Endothelin-A- and -B-Selective Radioligands for Positron Emission Tomography
  144. Tissue-Specific Modulation of Endothelin Receptors in a Rat Model of Hypertension
  145. Evidence for Intracellular Endothelin-Converting Enzyme-2 Expression in Cultured Human Vascular Endothelial Cells
  146. Blockade and Reversal of Endothelin-Induced Constriction in Pial Arteries From Human Brain   Editorial Comment
  147. Endothelin receptor expression and pharmacology in human saphenous vein graft
  148. Secretory pathways in endothelin synthesis
  149. The therapeutic potential of PD156707 and related butenolide endothelin antagonists
  150. The haemodynamic effects of iodinated water soluble radiographic contrast media: a review
  151. Expression of EndothelinA Receptors in Human Gliomas and Meningiomas, with High Affinity for the Selective Antagonist PD156707
  152. Increased response to big endothelin-1 in atherosclerotic human coronary artery: functional evidence for up-regulation of endothelin-converting enzyme activity in disease
  153. Human Endothelial Cell Storage Granules : A Novel Intracellular Site for Isoforms of the Endothelin-Converting Enzyme
  154. Endothelin receptor subtypes and their functional relevance in human small coronary arteries
  155. Evidence Using Immunoelectron Microscopy for Regulated and Constitutive Pathways in the Transport and Release of Endothelin
  156. In vitro enzymatic processing of radiolabelled big ET-1 in human kidney
  157. Characterization of [125I]-PD164333, an ETAselective non-peptide radiolabelled antagonist, in normal and diseased human tissues
  158. Characterization of Site-Directed Antisera Against Endothelin-Converting Enzymes
  159. Endothelin Peptide and Converting Enzymes in Human Endothelium
  160. Endothelin-Converting Enzyme in the Human Vasculature: Evidence for Differential Conversion of Big Endothelin-3 by Endothelial and Smooth-Muscle Cells
  161. PD156707: A Potent Antagonist of Endothelin-1 in Human Diseased Coronary Arteries and Vein Grafts
  162. Relative Contribution of Endothelin A and Endothelin B Receptors to Vasoconstriction in Small Arteries from Human Heart and Brain
  163. Endothelin converting enzyme (ECE) activity in human vascular smooth muscle
  164. Detection of Endothelin Receptors in Human Coronary Artery Vascular Smooth Muscle Cells But Not Endothelial Cells by Using Electron Microscope Autoradiography
  165. Differential distribution of endothelin receptor subtypes in placentae from normal and growth-restricted pregnancies
  166. Differential distribution of endothelin peptides and receptors in human adrenal gland
  167. Characterization of the binding of endothelin ETB selective ligands in human and rat heart
  168. Endothelin Peptide and Receptors in Human Atherosclerotic Coronary Artery and Aorta
  169. Selective downregulation of ETA receptor mRNA in renal transplant recipients on cyclosporin A revealed by quantitative RT-PCR
  170. The increase in human plasma immunoreactive endothelin but not big endothelin-1 or its C-terminal fragment induced by systemic administration of the endothelin antagonist TAK-044
  171. Failure of BQ123, a more potent antagonist of sarafotoxin 6b than of endothelin-1, to distinguish between these agonists in binding experiments
  172. The endothelin system in the kidney
  173. Endothelin receptors in human coronary artery and aorta
  174. Characterization of the endothelin receptor selective agonist, BQ3020 and antagonists BQ123, FR139317, BQ788, 50235, Ro462005 and bosentan in the heart
  175. Localization of endothelin peptides in human kidney
  176. Endocrinology and paracrinology
  177. Radioligand Binding Assays: Theory and Practice
  178. Expression of Endothelin Peptides and Mrna in the Human Heart
  179. Endothelin ETA receptor expression in human cerebrovascular smooth muscle cells
  180. Phosphoramidon inhibition of the in vivo conversion of big endothelin-1 to endothelin-1 in the human forearm
  181. Endothelin expression in the uterus
  182. ETA receptor-mediated constrictor responses to endothelin peptides in human blood vessels in vitro
  183. Endothelin ETA and ETB mRNA and receptors expressed by smooth muscle in the human vasculature: majority of the ETA sub-type
  184. ETA and ETB endothelin receptors in human myometrium characterized by the subtype selective ligands BQ123, BQ3020, FR139317 and PD151242
  185. Secretion of endothelin-1 and endothelin-3 by human cultured vascular smooth muscle cells
  186. Selectivity of [125I]-PD 151242 for human, rat and porcine endothelin ETA receptors in the heart
  187. [125I]-PD151242: a selective ligand for endothelin ETA receptors in human kidney which localizes to renal vasculature
  188. Vasoconstrictor endothelin receptors characterized in human renal artery and vein in vitro
  189. Quantification of mRNA in Human Tissue Using Fluorescent Nested Reverse-Transcriptase Polymerase Chain Reaction
  190. Effects of Phosphoramidon and Pepstatin a on the Secretion of Endothelin-I and Big Endothelin-I by Human Umbilical Vein Endothelial Cells: Measurement by Two-Site Enzyme-Linked Immunosorbent Assays
  191. Effects of an ET1-receptor antagonist, FR139317, on regional haemodynamic responses to endothelin-1 and [Ala11,15]Ac-endothelin-1 (6-21) in conscious rats
  192. Davenport and Maguire reply
  193. Validation of mRNA Quantification in Human Kidney by a Novel Fluorescent Nested RT-PCR Method
  194. Is endothelin-induced vasoconstriction mediated only by ETA receptors in humans?
  195. [125I]-PD 151242: a selective radioligand for human ETA receptors
  196. Isolation of Human Cardiac Endothelin Receptors by a Peptide-Receptor Mobility Shift Assay
  197. Novel ligands BQ123 and BQ3020 characterize endothelin receptor subtypes ETA and ETB in human kidney
  198. Alternatively Spliced mRNAs for Human Endothelin-2 and Their Tissue Distribution
  199. Endothelin: progress in pharmacology and physiology
  200. Identification of endothelin-1, endothelin-2 and endothelin-3 in human endometrium
  201. Characterisation of Immunoreactive Endothelin in Human kidney by RP-HPLC and RIA
  202. Characterization and localization of endothelin receptor subtypes in the human atrioventricular conducting system and myocardium
  203. Quantitative autoradiography reveals higher densities of specific calcitonin-gene-related peptide receptors in small intramyocardial compared with large epicardial coronary arteries
  204. Presence of messenger ribonucleic acid for endothelin-1, endothelin-2, and endothelin-3 in human endometrium and a change in the ratio of ETA and ETB receptor subtype across the menstrual cycle.
  205. Presence of messenger ribonucleic acid for endothelin-1, endothelin-2, and endothelin-3 in human endometrium and a change in the ratio of ETA and ETB receptor subtype across the menstrual cycle
  206. Characterization of two new ETB selective radioligands, [125I]-BQ3020 and [125I]-[Ala1,3,11,15]ET-1 in human heart
  207. Anatomical localization and pharmacological activity of mature endothelins and their precursors in human vascular tissue
  208. Localization of immunoreactive endothelin and proendothelin in the human lung
  209. Endothelin-like immunoreactivity in human endometrium
  210. Cerebellar neurons and glia respond differentially to endothelins and sarafotoxin S6b
  211. Endothelins in reproduction
  212. Localization and endogenous concentration of endothelin-like immunoreactivity in human placenta
  213. Epidermal growth factor in human endometrium: proliferative effects in culture and immunocytochemical localization in normal and endometriotic tissues
  214. Binding sites for125I ET-1, ET-2, ET-3 and vasoactive intestinal contractor are present in adult rat brain and neurone-enriched primary cultures of embryonic brain cells
  215. Binding sites for iodinated endothelin-1, endothelin-2 and endothelin-3 demonstrated on human uterine glandular epithelial cells by quantitative high-resolution autoradiography
  216. Mitogenic Effects of Vasoactive Peptides on Rat Vascular Smooth Muscle Cells
  217. Endothelin-1 stimulates prostaglandin F2α release from human endometrium
  218. The endothelin peptides ET-1, ET-2, ET-3 and sarafotoxin S6b are co-mitogenic with platelet-derived growth factor for vascular smooth muscle cells
  219. Atrial natriuretic factor mRNA and binding sites in the adrenal gland
  220. Localisation off binding sites for iodinated endothelin and saraffotoxin peptides in mammalian tissues using quantitative receptor autoradiography
  221. Endothelin-1 mRNA is widely expressed in porcine and human tissues.
  222. A sensitive radioimmunoassay measuring endothelin-like immunoreactivity in human plasma: Comparison of levels in patients with essential hypertension and normotensive control subjects
  223. Binding Sites for125I-Labelled Endothelin-1 in the Kidneys: Differential Distribution in Rat, Pig and Man Demonstrated by Using Quantitative Autoradiography
  224. Experimental hemiparkinsonism in the rat following chronic unilateral infusion of MPP+ into the nigrostriatal dopamine pathway—II. Differential localization of dopamine and cholecystokinin receptors
  225. Comparison between brain paste and polymer [125I]standards for quantitative receptor autoradiography
  226. Effect of the formamidine insecticide chordimeform on feeding and reproduction in the noctuid moth, Spodoptera littoralis (Boisduval)
  227. Quantitative receptor autoradiography
  228. Sex-related differences in the concentration of Met-enkephalin-like immunoreactivity in the nervous system of an insect,Schistocerca gregaria, revealed by radioimmunoassay
  229. Octopamine distribution in the larvae and adults of two species of moth, Spodoptera littoralis and Manduca sexta
  230. The action of formamidines on octopamine receptors in the locust
  231. Toxicity of chlordimeform and amitraz to the egyptian cotton leafworm (Spodoptera littoralis) and the tobacco budworm (Heliothis virescens)
  232. Changes in haemolymph octopamine levels associated with food deprivation in the locust, Schistocerca gregaria
  233. Stress-induced changes in the octopamine levels of insect haemolymph
  234. Biogenic amines in the brain of the honeybee, Apis mellifera
  235. Dynamic In Vivo Imaging of Receptors in Small Animals Using Positron Emission Tomography
  236. Imaging and Characterization of Radioligands for Positron Emission Tomography Using Quantitative Phosphor Imaging Autoradiography
  237. Immunocytochemical Localization of Receptors Using Light and Confocal Microscopy With Application to the Phenotypic Characterization of Knock-Out Mice
  238. Radioligand-Binding and Molecular-Imaging Techniques for the Quantitative Analysis of Established and Emerging Orphan Receptor Systems
  239. Apelins and the Apelin Receptor
  240. Radioligand Binding Assays and Quantitative Autoradiography of Endothelin Receptors
  241. Analysis of Endothelins by Enzyme-Linked Immunosorbent Assay and Radioimmunoassay